Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMARCA4 | P51532 | 8/20 | 0.58 |
| ▸ | PBRM1 | Q86U86 | 6/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | CCR3 | P51677 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | SMARCA2 | P51531 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21992960 | 0.93 | SMARCA4 (0.60) | SMARCA4PBRM1NPC1RAB9ACCR3 | |
| SCHEMBL21992771 | 0.89 | PBRM1 (0.64) | SMARCA4PBRM1NPC1RAB9ACCR3 | |
| SCHEMBL21931876 | 0.88 | SMARCA4 (0.53) | SMARCA4PBRM1NPC1RAB9ACCR3 | |
| SCHEMBL30859443 | 0.88 | SMARCA4 (0.53) | SMARCA4PBRM1NPC1RAB9ACCR3 | |
| SCHEMBL21931877 | 0.88 | SMARCA4 (0.53) | SMARCA4PBRM1NPC1RAB9ACCR3 | |
| SCHEMBL25053621 | 0.88 | SMARCA4 (0.53) | SMARCA4PBRM1NPC1RAB9ACCR3 | |
| SCHEMBL30859440 | 0.87 | SMARCA4 (0.52) | SMARCA4PBRM1NPC1RAB9ACCR3 | |
| SCHEMBL20704901 | 0.87 | SMARCA4 (0.52) | SMARCA4PBRM1NPC1RAB9ACCR3 | |
| SCHEMBL25053615 | 0.84 | SMARCA4 (0.58) | SMARCA4PBRM1NPC1RAB9ACCR3 | |
| SCHEMBL21993752 | 0.83 | SMARCA4 (0.56) | SMARCA4PBRM1NPC1RAB9ACCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11583530-B2 | Compounds for the prevention and treatment of medical disorders and uses thereof | GALECTIN SCIENCES, LLC (US) | 2023-02-21 | — | — | US | disclosed |
| US-20200147088-A1 | Compounds for the Prevention and Treatment of Medical Disorders and Uses Thereof | GALECTIN SCIENCES, LLC | 2020-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200147088-A1 | Compounds for the Prevention and Treatment of Medical Disorders and Uses Thereof | LGALS1, LGALS2, LGALS3 | SMARCA4 4569/4885PBRM1 4399/4885NPC1 165/4885 |
| US-11583530-B2 | Compounds for the prevention and treatment of medical disorders and uses thereof | LGALS1, LGALS2, LGALS3 | SMARCA4 4569/4885PBRM1 4399/4885NPC1 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.